Opinion
Video
Panelists discuss how the combination of zanubrutinib plus venetoclax in arm D of the SEQUOIA trial contributes to understanding the potential role of BTK inhibitor and BCL2 inhibitor combinations in frontline CLL treatment.
Video content above is prompted by the following: